Article Text

PDF
Langerhans cell histiocytosis
  1. K Windebank1,
  2. V Nanduri2
  1. 1
    Newcastle University, Newcastle upon Tyne, UK
  2. 2
    Watford General Hospital, Watford, UK
  1. Correspondence to Dr K Windebank, Child Health, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; k.p.windebank{at}ncl.ac.uk

Abstract

Langerhans cell histiocytosis is a rare disease. Depending on which organs are involved, the disease may prove rapidly fatal, develop a chronic reactivating but therapy-responsive pattern or resolve spontaneously. Understanding of the pathology of the disease is progressing rapidly, and while clinical trials of standard chemotherapy agents continue, it is likely that novel targeted therapy will become feasible in the next decade. Permanent consequences of the disease are more commoner than generally realised.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and Peer review Commissioned; externally peer reviewed.

  • Patient consent Obtained from the parents.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.